{
  "pmcid": "11831364",
  "sha256": "a81ca0cf4d6fda4a1a42b83c0b0070eaa636807b9cae36373fd4fb4a9d50b24c",
  "timestamp_utc": "2025-11-09T22:08:49.359084+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.428108108108109,
    "reading_ease": 42.26531531531532,
    "word_count": 222
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Decellularized Dermis Allograft for Venous Leg Ulcers: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised 1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were adults with VLUs ≥3 months and ≥2 cm², with venous incompetence and an ankle-brachial pressure index ≥0.8."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to receive either DCD allograft plus standard care or standard care alone."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial evaluated the effectiveness of decellularized dermis (DCD) allografts as an adjunctive treatment for VLUs."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the proportion of patients with a healed index ulcer at 12 weeks."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was automated"
      },
      "Blinding": {
        "score": 1,
        "evidence": "outcome assessors were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From October 2019 to October 2022, 71 participants were randomised (36 to intervention, 35 to control)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Healing occurred in 5.7% of the intervention group and 15.2% of the control group (OR 0.34, 95% CI 0.03 to 2.31)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Five serious adverse events were attributed to DCD."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ISRCTN 21541209"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: JP Moulton Charitable Trust"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}